NKP-1339

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameNKP-1339
Drug Alias NameBOLD-100KP-1339NKP-1339IT-139
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 mitogen-activated protein kinase inhibitors78 kDa glucose-regulated protein inhibitors
TargetsP38 mitogen-activated protein kinase78 kDa glucose-regulated protein
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsStomach Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesItaly +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMedizinische Universitaet Wien
China Registration ClassN/A

Develop Information

Active CompaniesBold Therapeutics IncUniversity Health Network (Uhn)Hana Pharmaceutical Co Ltd
Inactive CompaniesNiiki Pharma Inc
Active IndicationsPancreatic NeoplasmsStomach NeoplasmsColorectal Neoplasms +[6] 
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A